

Cover Story
By Matthew Bin Han Ong
For more than four decades, Steven Rosenberg's work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.
By Jordan Williams
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- George Sigounas named the first-ever chief science advisor at NCI
- Makary: Level of evidence is an artificial and dogmatic construct
- The other side of the patient portal: Reflections from a cancer center leader
- Surviving cancer is often not a patient’s most challenging battle